Overview

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well dasatinib works in treating patients with advanced liver cancer that cannot be removed by surgery. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Dasatinib